

MAR 17 2005

Subst. Form PTO-1449  APPLICANT'S INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 18525/04011	Serial No.: 09/632,036
	Applicant: Kaumaya, et al.	
	Filing Date: August 3, 2000	Group: 1642

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
SR	AA	5,876,712	March 2, 1999	Cheever, et al.			Jun. 6, 1995
	AB						

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
SR	AC	94/07531	April 14, 1994	WO			
	AD	97/38011	October 16, 1997	WO			

## OTHER PRIOR ART

SR	AE	<del>Supplementary European Search Report dated August 10, 2004.</del>					
SR	AF	"Peptide Vaccines Incorporating a "Promiscuous" T-cell Epitope bypass Certain Haplotype Restricted Immune Responses and Provide Broad Spectrum Immunogenicity" by Kaumaya, et al., <u>Journal of Molecular Recognition</u> , Vol. 6, 81-94 (1993).					
	AG	"Human T-Lymphotropic Virus Type 1 Peptides in Chimeric and Multivalent Constructs with Promiscuous T-Cell Epitopes Enhance Immunogenicity and Overcome Genetic Restriction" by Lairmore, et al., <u>Journal of Virology</u> , Oct. 1995, vol. 69, No. 10, p. 6077-6089.					
	AH	"Subunit Peptide Cancer Vaccines Targeting Activating Mutations of the p21 <i>RAS</i> Proto-Oncogene" by Triozi, et al., <u>Biomedical Peptides, Proteins and Nucleic Acids</u> , Vol. 1, 185-192 (1995).					
	AI	"Granulocyte-Macrophage Colony Stimulating Factor: An effective Adjuvant for Protein and Peptide-Based Vaccines" by Disis, et al., <u>Blood</u> , Vol. 88, No. 1, July 1, 1996, p. 202-210.					
	AJ	"Identification of HER2/neu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes" by Kono, et al., <u>Int. J. Cancer</u> , 78, 202-208 (1998).					
	AK	"Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary <i>in Vitro</i> Immunization with Peptide-pulsed Dendritic Cells" by Kawashima, et al., <u>Cancer Research</u> , 59, 431-435, January 15, 1999.					
	AL	"Immunization to Oncogenic HER-2/neu Protein with Peptide Based Vaccines" by Disis, et al., <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , New York, New York, Vol. 36, March 1995, p. 251.					
	AM	"T-Cell, Adhesion, and B-Cell Epitopes of the Cell Surface <i>Streptococcus mutans</i> Protein Antigen I/II" by Kelly, et al., <u>Infection and Immunity</u> , Vol. 63, No. 9, Sept. 1995, p 3649-3658.					
	AN	"Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing <i>P. vivax</i> CS epitopes in <i>Aotus</i> monkeys" by Herrera, et al., <u>Parasite Immunology</u> , 1997: 19: 161-170.					
	AO	"A novel human HER2-derived peptide homologous to the mouse K <sup>d</sup> -restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals" by Okugawa, et al., <u>Eur. J. Immunol</u> , 2000, 30:3338-3346.					
	AP	"A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses" by Dakappagari, et al., <u>The Journal of Immunology</u> , April 15, 2003, Vol. 170, No. 8, p. 4242-4253.					
	AQ	"Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide" by Frangione-Beebe, et al., <u>Vaccine</u> , 19 (2001) 1068-1081.					

Examiner:

Date Considered:

6/2/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.